The effectiveness of tivantinib for MET-high hepatocellular carcinoma: A protocol for meta analysis

Background: The efficacy of tivantinib for MET-high hepatocellular carcinoma remains controversial. We conduct this meta-analysis to explore the efficacy of tivantinib versus placebo for MET-high hepatocellular carcinoma.

Methods: We have searched PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through November 2022 and included randomized controlled trials (RCTs) assessing the efficacy and safety of tivantinib versus placebo for MET-high hepatocellular carcinoma.

Results: Three RCTs were included in the meta-analysis. Overall, compared with control group for MET-high hepatocellular carcinoma, tivantinib showed no obvious impact on overall survival (hazard ratio [HR] = 0.77; 95% confidence interval [CI] = 0.52-1.13; P = .18) or progression-free survival (HR = 0.78; 95% CI = 0.56-1.08; P = .14). In addition, tivantinib was associated with the increase in grade ≥3 neutropenia (odd ratio [OR] = 11.76; 95% CI = 2.77-49.89; P = .0008) and leukopenia (OR = 14; 95% CI = 1.68-116.82; P = .01), but demonstrated no impact on the incidence of grade ≥ 3 anemia (OR = 2.74; 95% CI = 0.14-53.43; P = .51).

Conclusions: Tivantinib may not benefit to the treatment of MET-high hepatocellular carcinoma.

 

Comments:

Based on the meta-analysis conducted, the efficacy of tivantinib for MET-high hepatocellular carcinoma appears to be inconclusive. The analysis included three randomized controlled trials (RCTs) that assessed the efficacy and safety of tivantinib compared to a placebo in this patient population.

The results of the meta-analysis indicated that tivantinib did not have a significant impact on overall survival (hazard ratio [HR] = 0.77; 95% confidence interval [CI] = 0.52-1.13; P = .18) or progression-free survival (HR = 0.78; 95% CI = 0.56-1.08; P = .14) when compared to the control group for MET-high hepatocellular carcinoma.

Furthermore, the use of tivantinib was associated with an increased risk of grade ≥3 neutropenia (odd ratio [OR] = 11.76; 95% CI = 2.77-49.89; P = .0008) and leukopenia (OR = 14; 95% CI = 1.68-116.82; P = .01). However, there was no significant impact on the incidence of grade ≥3 anemia (OR = 2.74; 95% CI = 0.14-53.43; P = .51).

Based on these findings, the meta-analysis suggests that tivantinib may not provide a benefit in the treatment of MET-high hepatocellular carcinoma. It is important to consider these results in the context of the limitations of the included studies and the need for further research to establish the efficacy and safety of tivantinib in this specific patient population.

Related Products

Cat.No.	Product Name	Information
S2753	Tivantinib	Tivantinib is the first non-ATP-competitive c-Met inhibitor with Ki of 0.355 μM in a cell-free assay, little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4. Tivantinib (ARQ 197) induces a G2/M arrest and apoptosis.

Related Targets

c-Met Apoptosis related